Transforming obesity: The advancement of multi-receptor drugs

Cites (219)

Items 201–206 of 206

1. Some aspects of the glucagon problem
   Berthet, Jacques · 1959 · The American Journal of Medicine
2. Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis
   Ali, Mahmoud M., Hafez, Ahmed, Abdelgalil, Mahmoud Shaban, Hasan, Mohammed Tarek, El-Ghannam, Mohammed Magdy, Ghogar, Osama M., Elrashedy, Asmaa Ahmed, Abd-ElGawad, Mohamed · 2022 · BMC Endocrine Disorders
3. Gastric inhibitory polypeptide receptor antagonism suppresses intramuscular adipose tissue accumulation and ameliorates sarcopenia
   Yuya Takahashi, Hiroki Fujita, Yusuke Seino, Satoko Hattori, Shihomi Hidaka, Tsuyoshi Miyakawa, Atsushi Suzuki, Hironori Waki, Daisuke Yabe, Yutaka Seino et al. · 2023 · Journal of Cachexia Sarcopenia and Muscle
4. Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
   IN YOUNG CHOI, JUNG KUK KIM, Jong Suk Lee · 2018 · Diabetes
5. 682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
   Yanyun Chen, Adam R. Mezo, Tamer Coşkun, Min Song, William C. Roell, Krister B. Bokvist, Julie S. Moyers, Melissa K. Thomas, FRANCISCO VALENZUELA, Hongchang Qu · 2021 · Diabetes
6. [Influence of glucagon and adrenalin on the in vitro synthesis of cholesterol by hepatic tissue].
   Jacques Berthet · 1958 · PubMed